Jubilant Ingrevia Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives (4)

Deepak Jain, Pavleen Taneja, Shyam S Bhartia, Varun Gupta

Analysts (7)

Abhijit Akella, Archit Joshi, Harsh Shah, Kiran Gadge, Nitesh Dhoot, Rohit Nagraj, Siddharth Gadekar

Financials & KPIs

Geographic & Segment Commentary

• Specialty Chemicals: Revenue of ₹533 crore (+11% YoY, +3% QoQ) with EBITDA of ₹139 crore at 26% margins. Growth driven by Fine Chemicals and CDMO, including rollout of large agro innovator CDMO volumes and a threefold-plus expansion in the pharma pipeline following US/Europe roadshows. Pyridine/picoline volumes steady at 95%+ utilization despite pricing pressure on commoditized pyridine variants; 20+ personal care products under development and a dedicated semicon R&D/clean room facility being built at Greater Noida.

• Nutrition & Health: Revenue of ₹243 crore (+36% YoY, +6% QoQ) with highest segment EBITDA in 3 years at ₹36 crore (15% margin). Niacinamide volumes grew steadily with strong pricing across food and cosmetics applications; choline chloride, CBT and vitamin B3 pricing improved substantially. Remidex Pharma integration complete, strengthening Tier 1 human nutrition customer presence in India. New 5,000 TPA niacinamide plant operating at 50%+ of peak run rate, targeting 70%+ by year-end.

• Chemical Intermediates: Revenue of ₹524 crore (+38% YoY, +21% QoQ) and EBITDA of ₹57 crore (+240% YoY, +163% QoQ) on robust demand, price escalations and effective input cost pass-throughs. Management sees continued momentum in Q2 backed by recent oil price escalations but acknowledges inherent segment volatility.

Company-Specific & Strategic Commentary

• Pinnacle Strategy: Delivering visible results with strong revenue/EBITDA growth and an improving opportunity pipeline; management believes FY27 will be a pivotal year, with growth led by Specialty Chemicals and Nutrition alongside acetyls recovery.

• CDMO & Fine Chemicals Pipeline: Funnel of 100+ molecules with ₹3,500+ crore peak revenue potential and 25+ confirmed molecules (5 added in Q1). Agro segment benefiting from big innovator CDMO volumes; pharma traction strong post-USA roadshow with 10 new opportunities generated from 7 customer meetings.

• Capacity Expansion: New multipurpose plant (MPP) on track for commissioning by end of calendar year 2026, strengthening the CDMO and Fine Chemicals growth roadmap; niacinamide plant scaling from 50%+ toward 70%+ of peak volumes by year-end.

• Semiconductors & Electronics: Dedicated R&D and clean room facility under construction at Greater Noida; encouraging growth in opportunity funnel with customers keen to partner for integrated opportunities.

• M&A & Integration: Remidex Pharma integration completed with encouraging Tier 1 human nutrition traction; actively evaluating growth opportunities in electronics, semiconductors, cosmetics and nutrition.

• Operations & ESG: Targeting ₹100 crore lean savings in FY27; Supernova program advancing Gen AI use cases; 20+ customer quality/EHS audits cleared in Q1; Gajraula, Bharuch and Nira sites recognized at British Safety Council International Safety Awards; certified Great Place to Work and ranked among top 50 manufacturing companies.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Large CDMO Contract – Volume Pause, Protection and Visibility

• Question: What was the contribution of the large CDMO contract in Q1, and did lower utilization mean the plant reported an EBITDA loss? (Siddharth Gadekar)
• Answer: Plant ran smoothly; supplies started in March and continued through Q1. The innovator requested a temporary pause mid-quarter as raw material prices escalated due to the war, but the segment still booked good positive EBITDA. If the customer gives no volumes under unforeseen circumstances, full protection more than covers communicated EBITDA expectations. (Deepak Jain)
• Question: Will Q2 volumes be higher, and when will the customer provide full volume visibility? (Harsh Shah)
• Answer: Q2 volumes will be higher than Q1. The customer has not given a firm timeline; clarity is needed within the next month for Q3 planning. (Deepak Jain)

CDMO Pipeline – Composition, Movement and Revenue Potential

• Question: Can you break out the ₹1,500 crore confirmed order book by end-use industry, and how is peak value arrived at for early-stage molecules? (Abhijit Akella)
• Answer: Mix is approximately 20–25% agro, ~30% pharma, 10–15% industrial, 15% nutrition and 10% consumer. Peak potential is based on customer-provided volume visibility over 2–4 years; a couple of molecules including the large agro contract are backed by contracts, while others are confirmed at first commercial supply. (Deepak Jain)
• Question: Why is the advanced-stage bucket static at 10 molecules for two straight quarters? (Nitesh Dhoot)
• Answer: The funnel is dynamic – molecules move from advanced to confirmed as new ones enter advanced stage. Following meetings with 7 US customers, at least 10 new opportunities have emerged that are not yet reflected in announced numbers. (Deepak Jain)
• Question: Why wasn't the ₹1,500 crore confirmed potential updated despite adding 5 molecules? (Siddharth Gadekar)
• Answer: The 5 new molecules (pharma/personal care) are early-stage; peak potential visibility is not yet available from customers. Upside will be added to confirmed potential as clarity emerges. (Deepak Jain)

FY27 Guidance – Maintained at ₹750–800 Crore

• Question: Given ₹209 crore Q1 EBITDA and sequential growth commentary, will FY27 guidance be upgraded? (Abhijit Akella)
• Answer: Guidance maintained at ₹750–800 crore, with H1 expected around ₹400 crore+. Specialty and Nutrition contribute 70–80% of EBITDA; Chemical Intermediates will contribute ~₹100 crore for the year. Acetyls momentum and booked orders could drive upside, but Q3/Q4 market volatility keeps guidance conservative. (Varun Gupta; Deepak Jain)

Specialty Chemicals – Sequential Performance Explained

• Question: Sequential revenue growth was only ₹17 crore with flat EBITDA despite plant commercialization – does this imply ex-CDMO decline or pricing pressure? (Nitesh Dhoot)
• Answer: Q4 is seasonally heavy due to customer year-end purchasing; Q1 naturally sees a step-down. CDMO volumes were not fully served as the customer asked for a pause on raw material price escalation. Pyridine volumes were stable with some price decline; Fine Chemicals remained strong off a high base. YoY comparison (+11%) is the more representative view. (Deepak Jain)

Nutrition – Pricing Sustainability and Niacinamide Scale-up

• Question: Does the earlier guidance that Q1 inventory benefits fade from Q2 still hold? What is the plant utilization and expected FY27 Nutrition EBITDA? (Nitesh Dhoot)
• Answer: Impact of Q1 inventory carryover into Q2 will be minimal – inventory buildup was careful, finished goods prices did not crash as feared, and the restart of the war is pushing prices up again in certain segments. The 5,000 TPA niacinamide plant is already at 50%+ of peak run rate, targeting 70%+ by year-end. (Deepak Jain)
• Question: Are B3 volumes steady, and is the ₹28 crore EBIT sustainable? (Archit Joshi)
• Answer: B3 volumes grew at the overall segment level. Pricing typically stays elevated for 2–3 quarters; Q2 bookings are largely done. Prices may soften by end of Q2, potentially impacting Q3, but the rising high-value mix (food, pharma, cosmetic grade) and cost improvement programs should protect margins. (Deepak Jain)

Pyridine – Leadership, Pricing and Captive Consumption

• Question: How is base pyridine pricing, and what is the captive vs external sales ratio? (Archit Joshi)
• Answer: Plant is running at 95%+ utilization across 60+ products. Pricing pressure is limited to commoditized building-block variants due to Chinese overcapacity; advanced derivatives and picolines are holding up. Captive consumption ratio is not disclosed but is increasing YoY, with beta-picoline consumption rising in line with growing B3 volumes. (Deepak Jain)

Cost Inflation – Power, Fuel and Logistics

• Question: Despite renewable investments, power/fuel and other expenses rose sharply – what explains this, and will power/fuel decline going forward? (Harsh Shah)
• Answer: Power/fuel increased due to higher volumes and Gulf crisis-driven increases in LSHS/natural gas costs. Other expenses rose mainly from logistics cost inflation (domestic and international), which was successfully passed on to customers through higher pricing. (Varun Gupta)

Chemical Intermediates – Sustainability of Rebound

• Question: ~₹40 crore of the ₹56 crore YoY EBITDA increase came from Chemical Intermediates – will this sustain, and were there inventory gains? (Rohit Nagraj)
• Answer: The portfolio approach means different segments fire in different quarters; over the last 12 quarters, quarterly EBITDA has grown from ~₹100 crore to ₹209 crore. Confidence is anchored in the overall committed guidance rather than any single segment, given each business has its own nuances and drivers. (Deepak Jain)

Key Takeaway

Jubilant Ingrevia opened FY27 with its strongest quarter in 15 periods, reporting revenue of ₹1,300 crore (+25% YoY), EBITDA of ₹209 crore (+36% YoY, +22% QoQ) and PAT of ₹106 crore (+41% YoY). Specialty Chemicals (₹533 crore, +11% YoY, 26% margins) and Nutrition (₹243 crore, +36% YoY, highest segment EBITDA in three years) led growth, while Chemical Intermediates rebounded sharply (₹524 crore, +38% YoY) on acetyls recovery. The CDMO pipeline reached 100+ molecules with ₹3,500+ crore peak revenue potential and 25+ confirmed molecules, underpinning the Pinnacle strategy. Management maintained FY27 EBITDA guidance of ₹750–800 crore with sequential improvement expected, H1 at ~₹400 crore+, and the niacinamide plant scaling from 50%+ to 70%+ of peak volumes by year-end. Key watch points include large agro CDMO volume visibility (clarity expected within a month), pyridine pricing pressure from Chinese overcapacity, B3 pricing cyclicality, and Middle East-driven input and logistics cost inflation.